vs
Orthofix Medical Inc.（OFIX）与UNIVERSAL TECHNICAL INSTITUTE INC（UTI）财务数据对比。点击上方公司名可切换其他公司
UNIVERSAL TECHNICAL INSTITUTE INC的季度营收约是Orthofix Medical Inc.的1.0倍（$220.8M vs $219.9M），UNIVERSAL TECHNICAL INSTITUTE INC净利率更高（5.8% vs -1.0%，领先6.8%），UNIVERSAL TECHNICAL INSTITUTE INC同比增速更快（9.6% vs 2.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $-19.2M），过去两年UNIVERSAL TECHNICAL INSTITUTE INC的营收复合增速更高（9.5% vs 8.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
环球技术学院（UTI）是美国的营利性私立技术院校集团，1965年由罗伯特·斯威特创立，专注于提供职业技术类教育课程，培养符合产业需求的技能型人才，在美职业教育领域拥有较长的运营历史与行业经验。
OFIX vs UTI — 直观对比
营收规模更大
UTI
是对方的1.0倍
$219.9M
营收增速更快
UTI
高出7.7%
2.0%
净利率更高
UTI
高出6.8%
-1.0%
自由现金流更多
OFIX
多$36.0M
$-19.2M
两年增速更快
UTI
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $220.8M |
| 净利润 | $-2.2M | $12.8M |
| 毛利率 | 71.1% | — |
| 营业利润率 | 0.2% | 7.1% |
| 净利率 | -1.0% | 5.8% |
| 营收同比 | 2.0% | 9.6% |
| 净利润同比 | 92.4% | -42.1% |
| 每股收益（稀释后） | $-0.05 | $0.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXUTI
| Q4 25 | $219.9M | $220.8M | ||
| Q3 25 | $205.6M | $222.4M | ||
| Q2 25 | $203.1M | $204.3M | ||
| Q1 25 | $193.6M | $207.4M | ||
| Q4 24 | $215.7M | $201.4M | ||
| Q3 24 | $196.6M | $196.4M | ||
| Q2 24 | $198.6M | $177.5M | ||
| Q1 24 | $188.6M | $184.2M |
净利润OFIXUTI
| Q4 25 | $-2.2M | $12.8M | ||
| Q3 25 | $-22.8M | $18.8M | ||
| Q2 25 | $-14.1M | $10.7M | ||
| Q1 25 | $-53.1M | $11.4M | ||
| Q4 24 | $-29.1M | $22.2M | ||
| Q3 24 | $-27.4M | $18.8M | ||
| Q2 24 | $-33.4M | $5.0M | ||
| Q1 24 | $-36.0M | $7.8M |
毛利率OFIXUTI
| Q4 25 | 71.1% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — | ||
| Q1 24 | 67.5% | — |
营业利润率OFIXUTI
| Q4 25 | 0.2% | 7.1% | ||
| Q3 25 | -8.3% | 11.2% | ||
| Q2 25 | -7.9% | 6.9% | ||
| Q1 25 | -25.2% | 8.1% | ||
| Q4 24 | -5.3% | 13.6% | ||
| Q3 24 | -9.6% | 13.3% | ||
| Q2 24 | -12.5% | 4.2% | ||
| Q1 24 | -15.6% | 6.1% |
净利率OFIXUTI
| Q4 25 | -1.0% | 5.8% | ||
| Q3 25 | -11.1% | 8.4% | ||
| Q2 25 | -6.9% | 5.2% | ||
| Q1 25 | -27.4% | 5.5% | ||
| Q4 24 | -13.5% | 11.0% | ||
| Q3 24 | -13.9% | 9.6% | ||
| Q2 24 | -16.8% | 2.8% | ||
| Q1 24 | -19.1% | 4.2% |
每股收益（稀释后）OFIXUTI
| Q4 25 | $-0.05 | $0.23 | ||
| Q3 25 | $-0.57 | $0.33 | ||
| Q2 25 | $-0.36 | $0.19 | ||
| Q1 25 | $-1.35 | $0.21 | ||
| Q4 24 | $-0.76 | $0.40 | ||
| Q3 24 | $-0.71 | $0.35 | ||
| Q2 24 | $-0.88 | $0.09 | ||
| Q1 24 | $-0.95 | $0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $162.8M |
| 总债务越低越好 | — | $101.4M |
| 股东权益账面价值 | $450.0M | $335.9M |
| 总资产 | $850.6M | $834.0M |
| 负债/权益比越低杠杆越低 | — | 0.30× |
8季度趋势，按日历期对齐
现金及短期投资OFIXUTI
| Q4 25 | $82.0M | $162.8M | ||
| Q3 25 | $62.9M | $169.1M | ||
| Q2 25 | $65.6M | $70.7M | ||
| Q1 25 | $58.0M | $96.0M | ||
| Q4 24 | $83.2M | $172.0M | ||
| Q3 24 | $30.1M | $161.9M | ||
| Q2 24 | $26.4M | $115.5M | ||
| Q1 24 | $27.0M | $116.1M |
总债务OFIXUTI
| Q4 25 | — | $101.4M | ||
| Q3 25 | $157.2M | $87.1M | ||
| Q2 25 | $157.0M | $73.8M | ||
| Q1 25 | $156.9M | $94.4M | ||
| Q4 24 | $157.0M | $120.1M | ||
| Q3 24 | $118.5M | $125.7M | ||
| Q2 24 | $118.0M | $137.3M | ||
| Q1 24 | $118.2M | $141.9M |
股东权益OFIXUTI
| Q4 25 | $450.0M | $335.9M | ||
| Q3 25 | $442.5M | $328.1M | ||
| Q2 25 | $458.3M | $306.8M | ||
| Q1 25 | $458.3M | $293.9M | ||
| Q4 24 | $503.1M | $280.0M | ||
| Q3 24 | $525.9M | $260.2M | ||
| Q2 24 | $546.0M | $239.4M | ||
| Q1 24 | $570.3M | $232.6M |
总资产OFIXUTI
| Q4 25 | $850.6M | $834.0M | ||
| Q3 25 | $832.6M | $826.1M | ||
| Q2 25 | $837.2M | $740.8M | ||
| Q1 25 | $823.1M | $720.4M | ||
| Q4 24 | $893.3M | $753.8M | ||
| Q3 24 | $867.9M | $744.6M | ||
| Q2 24 | $882.0M | $706.0M | ||
| Q1 24 | $906.0M | $702.1M |
负债/权益比OFIXUTI
| Q4 25 | — | 0.30× | ||
| Q3 25 | 0.36× | 0.27× | ||
| Q2 25 | 0.34× | 0.24× | ||
| Q1 25 | 0.34× | 0.32× | ||
| Q4 24 | 0.31× | 0.43× | ||
| Q3 24 | 0.23× | 0.48× | ||
| Q2 24 | 0.22× | 0.57× | ||
| Q1 24 | 0.21× | 0.61× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $3.1M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $-19.2M |
| 自由现金流率自由现金流/营收 | 7.6% | -8.7% |
| 资本支出强度资本支出/营收 | 4.9% | 10.1% |
| 现金转化率经营现金流/净利润 | — | 0.24× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $16.6M |
8季度趋势，按日历期对齐
经营现金流OFIXUTI
| Q4 25 | $27.7M | $3.1M | ||
| Q3 25 | $12.4M | $57.1M | ||
| Q2 25 | $11.6M | $18.1M | ||
| Q1 25 | $-18.4M | $-789.0K | ||
| Q4 24 | $23.7M | $23.0M | ||
| Q3 24 | $11.7M | $67.5M | ||
| Q2 24 | $9.0M | $10.0M | ||
| Q1 24 | $-18.6M | $-2.5M |
自由现金流OFIXUTI
| Q4 25 | $16.8M | $-19.2M | ||
| Q3 25 | $2.5M | $40.6M | ||
| Q2 25 | $4.5M | $6.8M | ||
| Q1 25 | $-25.1M | $-11.7M | ||
| Q4 24 | $15.2M | $19.6M | ||
| Q3 24 | $6.3M | $60.0M | ||
| Q2 24 | $-360.0K | $3.0M | ||
| Q1 24 | $-29.1M | $-8.4M |
自由现金流率OFIXUTI
| Q4 25 | 7.6% | -8.7% | ||
| Q3 25 | 1.2% | 18.3% | ||
| Q2 25 | 2.2% | 3.4% | ||
| Q1 25 | -13.0% | -5.7% | ||
| Q4 24 | 7.0% | 9.7% | ||
| Q3 24 | 3.2% | 30.6% | ||
| Q2 24 | -0.2% | 1.7% | ||
| Q1 24 | -15.4% | -4.6% |
资本支出强度OFIXUTI
| Q4 25 | 4.9% | 10.1% | ||
| Q3 25 | 4.8% | 7.4% | ||
| Q2 25 | 3.5% | 5.5% | ||
| Q1 25 | 3.5% | 5.3% | ||
| Q4 24 | 4.0% | 1.7% | ||
| Q3 24 | 2.7% | 3.8% | ||
| Q2 24 | 4.7% | 4.0% | ||
| Q1 24 | 5.6% | 3.2% |
现金转化率OFIXUTI
| Q4 25 | — | 0.24× | ||
| Q3 25 | — | 3.04× | ||
| Q2 25 | — | 1.69× | ||
| Q1 25 | — | -0.07× | ||
| Q4 24 | — | 1.04× | ||
| Q3 24 | — | 3.58× | ||
| Q2 24 | — | 2.01× | ||
| Q1 24 | — | -0.32× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
UTI
| UTI | $142.8M | 65% |
| Concorde | $78.0M | 35% |
